SEARCH

SEARCH BY CITATION

References

  • 1
    Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326:3637.
  • 2
    Buchbinder R, Forbes A, Hall S et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134:108795.
  • 3
    Zampieri S, Valente M, Adami N et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev 2010; 9:44953.
  • 4
    Hill CL, Zhang Y, Sigurgeirsson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357:96100.
  • 5
    András C, Ponyi A, Constantin T et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008; 35:43844.
  • 6
    Naschitz JE, Rosner I, Rozenbaum M et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum 1999; 29:4355.
  • 7
    Bonnetblanc JM, Bernard P, Fayol J. Dermatomyositis and malignancy. A multicenter cooperative study. Dermatologica 1990; 180:21216.
  • 8
    Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995; 22:13003.
  • 9
    Sparsa A, Liozon E, Herrmann F et al. Routine versus extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 2002; 138:88590.
  • 10
    Basset-Seguin N, Roujeau JC, Gherardi R et al. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol 1990; 126:6337.
  • 11
    Nishikai M, Sato A. Low incidence of antinuclear antibodies in dermatomyositis with malignancy. Ann Rheum Dis 1990; 49:422.
  • 12
    Duncan AG, Richardson JB, Klein JB et al. Clinical, serologic, and immunogenetic studies in patients with dermatomyositis. Acta Derm Venereol 1991; 71:31216.
  • 13
    Gallais V, Crickx B, Belaich S. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. Ann Dermatol Venereol 1996; 123:7226.
  • 14
    Whitmore SE, Anhalt GJ, Provost TT et al. Serum CA-125 screening for ovarian cancer in patients with dermatomyositis. Gynecol Oncol 1997; 65:2414.
  • 15
    Hidano A, Torikai S, Uemura T, Shimizu S. Malignancy and interstitial pneumonitis as fatal complications in dermatomyositis. J Dermatol 1992; 19:15360.
  • 16
    Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292:4037.
  • 17
    Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292:3447.
  • 18
    Wells GA, Shea B, O'Connell D et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (last accessed 6 August 2013).
  • 19
    Antiochos BB, Brown LA, Li Z et al. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, U.S.A. J Rheumatol 2009; 36:270410.
  • 20
    So MW, Koo BS, Kim YG et al. Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol 2011; 38:24325.
  • 21
    Ponyi A, Constantin T, Garami M et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 2005; 1051:6471.
  • 22
    Prohic A, Kasumagic-Halilovic E, Simic D, Selmanagic A. Clinical and biological factors predictive of malignancy in dermatomyositis. J Eur Acad Dermatol Venereol 2009; 23:5912.
  • 23
    Fardet L, Dupuy A, Gain M et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009; 88:917.
  • 24
    Azuma K, Yamada H, Ohkubo M et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 2011; 21:17883.
  • 25
    Amerio P, Girardelli CR, Proietto G et al. Usefulness of erythrocyte sedimentation rate as tumor marker in cancer associated dermatomyositis. Eur J Dermatol 2002; 12:1659.
  • 26
    Wu XN. Clinical analysis of 147 patients with dermatomyositis. Master's degree thesis, Sun Yat-Sen University, 2010.
  • 27
    Lian L, Xu JH. Clinical analysis of 20 patients with polymyositis/dermatomyositis associated with malignancy. J Clin Intern Med 2005; 22:1617.
  • 28
    Zou Y, Yang YX, Chen XP. Clinical analysis of 22 patients with dermatomyositis and polymyositis complicating malignancy. J Pract Dermatol 2009; 2:913.
  • 29
    Tang FL, Zhao JS, Zhang XH. Malignancy in patients with dermatomyositis/polymyositis. Chin J Rheumatol 2000; 4:757.
  • 30
    Yu XH, Liu XM. Clinical analysis of malignancy and death in dermatomyositis. Chin J Derm Venereol 2004; 18:5445.
  • 31
    Zhou YN, Chen AM, Zhou NH. Clinical analysis of patients with dermatomyositis complicated with malignancies. J Clin Dermatol 2012; 41:1335.
  • 32
    Chen Y, Wang GC. Retrospective study of idiopathic inflammatory myopathies associated with malignancy. Chin J Clin 2008; 2:64551.
  • 33
    Rose C, Hatron PY, Brouillard M et al. Predictive signs of cancers in dermatomyositis. Study of 29 cases. Rev Med Interne 1994; 15:1924.
  • 34
    Burnouf M, Mahé E, Verpillat P et al. Cutaneous necrosis is predictive of cancer in adult dermatomyositis. Ann Dermatol Venereol 2003; 130:31316.
  • 35
    Hunger RE, Durr C, Brand CU. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology 2001; 202:1236.
  • 36
    Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O'Callaghan A et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64:52332.
  • 37
    Targoff IN, Mamyrova G, Trieu EP et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54:36829.
  • 38
    Yoshifuji H, Fujii T, Kobayashi S et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39:23341.
  • 39
    Barral PM, Sarkar D, Su ZZ et al. Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity. Pharmacol Ther 2009; 124:21934.
  • 40
    Nakashima R, Imura Y, Kobayashi S et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 2010; 49:43340.
  • 41
    Sato S, Hirakata M, Kuwana M et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52:15716.
  • 42
    Sato S, Hoshino K, Satoh T et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60:2193200.
  • 43
    Fiorentino D, Chung L, Zwerner J et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65:2534.
  • 44
    Gherardi RK. Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis. Presse Med 2011; 40:e20918.